Results 161 to 170 of about 952 (211)

Development and Clinical Utility of Machine Learning Models for Prediction of Same‐Day Discharge in Outpatient Hip and Knee Replacement: A Prognostic Study

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 8, September 2026.
ABSTRACT Background Hip and knee replacement are common procedures with an increasing focus on same‐day surgery. However, capacity constraints limit the number of eligible patients actually being scheduled for same‐day discharge, calling for further selection of those with the highest likelihood of same‐day discharge.
Christoffer C. Jørgensen, Jakob B. Frederiksen, Henrik Kehlet, Martin Lindberg‐Larsen, Kirill Gromov, Claus Varnum, Thomas Jakobsen, Manuel Josef Bieder, Mikkel Rathsach Andersen, Søren Overgaard, Torben B. Hansen, Troels Petersen   +11 more
wiley   +1 more source

Response to Letters to the Editor Regarding ‘Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From a Multi‐Center, Prospective, Observational Study (REVISE Study)’

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Jie‐Eun Lee, Jun Hwa Hong, Min Soo Song, Jong Chul Won   +3 more
wiley   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, Volume 14, Issue 6, Page 1627-1635, September 2026.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source

Immature Neutrophil Phenotype and Enhanced Myeloperoxidase in Male Patients With Chronic Kidney Disease and Cardiovascular Comorbidity

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT Aim Patients with chronic kidney disease (CKD) have an increased cardiovascular risk. Since neutrophils and neutrophil‐borne proteins contribute to cardiovascular disease, we analyzed the neutrophil phenotype in patients with CKD who presented with a spectrum of cardiovascular comorbidities.
Sonja Vondenhoff, Alessandra Antwerpen, Carolina Victoria Cruz Junho, Philipp Martin, Sina Hourtz, Jinmi Zou, Berkan Kurt, Carolin Haas, Susanne Fleig, Corinna Schulte, Jane Lauxen, Martina Wessiepe, Ulrike Späte‐Schulze, Rafael Kramann, Jürgen Floege, Oliver Soehnlein, Joachim Jankowski, Claudia Goettsch, Yvonne Döring, Florian Kahles, Nikolaus Marx, Constance C. F. M. J. Baaten, Heidi Noels   +22 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitor approaches.

Journal of diabetes, 2019
openaire   +1 more source

Triangulating the Skeletal Safety of SGLT2 Inhibitors in Diabetes

Journal of Diabetes, Volume 18, Issue 9, September 2026.
Bin Huang, Shujie Yu, Anran Su, Yi Zheng, Yue Teng, Wei Wang   +5 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dipeptidyl peptidase-4 inhibitors

Reactions Weekly, 2021
The dipeptidyl peptidase 4 (DPP-4) inhibitor has become a popular anti-diabetes medication since its introduction in 2006. They are small molecules that specifically bind to the catalytic domain of DPP-4, which consequently prevents the enzymatic inactivation of incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide)
Yoo Hyung Kim, Young Min Cho
openaire   +2 more sources

Effect of dipeptidyl peptidase‐4 inhibitors on complement activation

Diabetes/Metabolism Research and Reviews, 2020
AbstractBackgroundAdverse activation of the complement cascade in the innate immune system appears to be involved in development of vascular complications in diabetes. Dipeptidyl peptidase‐4 (DPP‐4) is a cell surface serine protease expressed in a variety of tissues.
Ingeborg T. Hoffmann‐Petersen, Charlotte B. Holt, Lisbeth Jensen, Camilla Hage, Linda G. Mellbin, Steffen Thiel, Troels K. Hansen, Jakob A. Østergaard   +7 more
openaire   +3 more sources

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

Drugs, 2011
The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretin hormones, represent a new therapeutic approach to the management of type 2 diabetes mellitus. The 'first-in-class' DPP-4 inhibitor, sitagliptin, was approved in
R. Baetta, A. Corsini
openaire   +2 more sources

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review

Clinical Therapeutics, 2011
Oral glucose-lowering agents are used to treat patients with type 2 diabetes mellitus (T2DM). Most patients require multiple agents to maintain glycemic targets. Dipeptidyl peptidase-4 (DPP-4) inhibitors are administered as monotherapy and in combination therapy for the treatment of T2DM.The aim of this article was to provide a thorough review of ...
Kathleen R, Richard, Jamie S, Shelburne, Julienne K, Kirk   +2 more
openaire   +2 more sources